Canaccord Genuity Group Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Analysts at Canaccord Genuity Group began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) in a research note issued to investors on Thursday, Marketbeat reports. The firm set a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 67.60% […]

Related Keywords

,Hc Advisors ,Trisalus Life Sciences Stock Down ,Canaccord Genuity Group ,Analysts At Canaccord Genuity Group ,Nasdaq ,News Ratings For Trisalus Life Sciences Daily ,Trisalus Life Sciences Inc ,Trisalus Life Sciences ,Get Free Report ,Genuity Group ,Salus Life Sciences Stock Down ,Salus Life Sciences ,Free Report ,Pressure Enabled Drug Delivery ,Pancreatic Retrograde Venous Infusion ,Trisalus Life Sciences Daily ,